ストックスクリーナーアプリを入手
29.34
0.43%
-0.4337
前日終値:
$29.77
開ける：
$29.74
24時間の取引高:
423.54K
Relative Volume:
0.25
時価総額：
$196.33M
収益：
-
当期純損益:
$-121.02M
株価収益率:
-2.6054
EPS:
-11.26
ネットキャッシュフロー:
$-114.09M
1週間 パフォーマンス:
+79.97%
1か月 パフォーマンス:
+251.61%
6か月 パフォーマンス:
+116.99%
1年 パフォーマンス:
-97.24%
1日の値動き範囲:
$28.56
$31.87
1週間の範囲:
$16.64
$37.83
52週間の値動き範囲:
$7.31
$1,146.01
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
名前
Tonix Pharmaceuticals Holding Corp
セクター
電話
212-980-9155
住所
26 MAIN STREET, SUITE 101, CHATHAM, NY
TNXP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
29.33 | 196.33M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.52 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.90 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
588.05 | 35.74B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.70 | 35.58B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.85 | 27.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-04-18 | 開始されました | Noble Capital Markets | Outperform |
| 2019-04-18 | アップグレード | ROTH Capital | Neutral → Buy |
| 2017-08-18 | アップグレード | ROTH Capital | Neutral → Buy |
| 2016-09-07 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2016-02-17 | 繰り返されました | Oppenheimer | Outperform |
| 2015-11-04 | 開始されました | Cantor Fitzgerald | Buy |
| 2015-06-12 | 開始されました | Oppenheimer | Outperform |
| 2015-02-17 | 繰り返されました | ROTH Capital | Buy |
| 2014-09-29 | 繰り返されました | ROTH Capital | Buy |
すべてを表示
Tonix Pharmaceuticals Holding Corp (TNXP) 最新ニュース
Tonix Pharmaceuticals: Potential To Have 'First' New Fibromyalgia Drug In 15 Years - Seeking Alpha
Noble Capital maintains Outperform on Tonix Pharma, $70 target By Investing.com - Investing.com South Africa
Noble Capital maintains Outperform on Tonix Pharma, $70 target - Investing.com
Tonix Pharmaceuticals: FDA AdCom News Positive, But Making Bull Case Is Problematic (TNXP) - Seeking Alpha
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Benzinga
Tonix advances fibromyalgia drug, eyes Q4 2025 launch By Investing.com - Investing.com Australia
Tonix Pharmaceuticals Says US FDA Will Not Require Committee Meeting to Discuss NDA for Fibromyalgia Treatment; Shares Up - Marketscreener.com
Tonix advances fibromyalgia drug, eyes Q4 2025 launch - Investing.com India
Tonix Pharmaceuticals Says US FDA Will Not Require Committee Meeting to Discuss NDA for Fibromyalgia Treatment - Marketscreener.com
Tonix Pharmaceuticals stock soars on FDA update By Investing.com - Investing.com Australia
Tonix Pharmaceuticals stock soars on FDA update - Investing.com
Tonix Pharma’s TNX-102 SL Advances in FDA Process - TipRanks
Tonix Pharmaceuticals Announces that FDA Will Not Require - GlobeNewswire
First New Fibromyalgia Treatment in 15 Years Advances: FDA Expedites TNX-102 SL Review - StockTitan
Tonix Pharmaceuticals Stock Dives After Q4 Earnings Miss, But Retail’s Feeling Bullish - MSN
As Mpox Cases Spread Around the World, Tonix Pharmaceuticals’ Single-Dose Vaccine TNX-801 Has Potential to Slow the Spread - ACCESS Newswire
New Single-Dose Mpox Vaccine Outperforms Existing Options as Cases Surge Worldwide - StockTitan
Tonix Pharma stock drops after Q4 revenue miss (TNXP:NASDAQ) - Seeking Alpha
Absci Posts Downbeat Results, Joins HealthEquity, Tonix Pharmaceuticals And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
Why StoneCo Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket - Benzinga
Tonix Pharmaceuticals Reports 2024 Financial Results and Pipeline Progress - TipRanks
Tonix Pharmaceuticals stock tumbles on earnings miss - Investing.com India
Tonix Pharma earnings missed by $5.86, revenue fell short of estimates - Investing.com
Tonix Pharmaceuticals stock tumbles on earnings miss By Investing.com - Investing.com Australia
Tonix Pharmaceuticals Holding Corp. SEC 10-K Report - TradingView
Tonix Pharmaceuticals 8-K Filing Analysis - TradingView
Tonix Pharmaceuticals Holding Corp. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights - GlobeNewswire
Tonix Secures Path to First New Fibromyalgia Drug in 15 Years with $98.8M War Chest - StockTitan
Learn to Evaluate (TNXP) using the Charts - Stock Traders Daily
* Tonix pharmaceuticals announces 1-for-10 reverse stock split - Reuters.com
Tonix Pharmaceuticals secures MCDC grant to advance next-gen Mpox & Smallpox vaccine development - Proactive Investors USA
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - The Manila Times
Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring 2025 - GlobeNewswire
Major FDA Decision Looms: Tonix's Revolutionary Fibromyalgia Treatment Could End 15-Year Innovation Drought - StockTitan
Tonix’s TNX-1500 Shows Promise in Preventing Organ Transplant Rejections of Either Human or Pig Organs; Autoimmune Diseases Also a Target - BioSpace
Tonix's TNX-1500 Shows Promise in Preventing Organ Transplant Re - NEWS CHANNEL NEBRASKA
Why Tonix Pharmaceuticals Holding Corp. (TNXP) Soared Last Week - MSN
Tonix Pharmaceuticals to Present at the Zacks SCR Life Sciences Virtual Investor Forum on March 13th - GlobeNewswire
Tonix Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum - Nasdaq
Tonix Unveils FDA Timeline and Pipeline Progress: Live Q&A with CEO March 13 - StockTitan
Tonix Pharma Secures Grant for TNX-801 Vaccine Development - TipRanks
Tonix Pharmaceuticals receives MCDC grant for devloping its single-dose Mpox and Smallpox vaccine - Marketscreener.com
Tonix Pharmaceuticals Announces Grant by Medical CBRN - GlobeNewswire
MCDC Grant Backs Tonix's Next-Gen Single-Dose Mpox Vaccine TNX-801 - StockTitan
10 Micro-, Small-Cap Firms Were Last Week’s Top Performers - Insider Monkey
Why Tonix Pharmaceuticals Holding Corp. (TNXP) Soared on Thursday - MSN
Tonix Pharmaceuticals Holding Corp (TNXP) 財務データ
収益
当期純利益
現金流量
EPS
1.66%
4.32%
大文字化:
|
ボリューム (24 時間):